| P50 | author | Stephan Hohmann | Q51117532 |
| P2093 | author name string | T König | |
| | D Duncker | |
| | C Veltmann | |
| P2860 | cites work | Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy | Q24197872 |
| | Long-QT syndrome: from genetics to management | Q26823298 |
| | Risk stratification in the long-QT syndrome. | Q33148941 |
| | Modulating effects of age and gender on the clinical course of long QT syndrome by genotype | Q33149140 |
| | Short QT Syndrome: a familial cause of sudden death | Q33149259 |
| | Determinants of Sudden Cardiac Death in Individuals With the Electrocardiographic Pattern of Brugada Syndrome and No Previous Cardiac Arrest | Q33150723 |
| | Congenital short QT syndrome and implantable cardioverter defibrillator treatment: inherent risk for inappropriate shock delivery | Q33150805 |
| | Corrected QT variability in serial electrocardiograms in long QT syndrome: the importance of the maximum corrected QT for risk stratification | Q33154233 |
| | Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy | Q33155374 |
| | Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia | Q33157356 |
| | Prevention of inappropriate ICD shocks in patients with Brugada syndrome | Q33157823 |
| | Risk stratification in electrical cardiomyopathies | Q33158278 |
| | Long-term prognosis of patients diagnosed with Brugada syndrome: Results from the FINGER Brugada Syndrome Registry | Q33158291 |
| | Implantable cardioverter defibrillator therapy for congenital long QT syndrome: A single-center experience | Q33159156 |
| | Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia | Q33159716 |
| | Long-term follow-up of patients with short QT syndrome | Q33160301 |
| | Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments | Q33160416 |
| | Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. | Q33160801 |
| | Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications | Q33162773 |
| | Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study-part 2. | Q33163218 |
| | Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia. | Q33163389 |
| | A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). | Q33163399 |
| | Atrial fibrillation in a large population with Brugada electrocardiographic pattern: prevalence, management, and correlation with prognosis. | Q33163804 |
| | Long-term prognosis in patients with Brugada syndrome based on Class II indication for implantable cardioverter-defibrillator in the HRS/EHRA/APHRS Expert Consensus Statement: multicenter study in Japan | Q33164471 |
| | 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). | Q33164685 |
| | Efficacy of different beta-blockers in the treatment of long QT syndrome | Q33164773 |
| | Syncope in Brugada syndrome: prevalence, clinical significance, and clues from history taking to distinguish arrhythmic from nonarrhythmic causes | Q33164862 |
| | Risk stratification in patients with Brugada syndrome without previous cardiac arrest – prognostic value of combined risk factors | Q33164977 |
| | Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year single-center experience | Q33165377 |
| | Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. | Q33175663 |
| | Influence of the genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. | Q33175786 |
| | Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them?: data from the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry | Q33691189 |
| | Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry | Q33827116 |
| | Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. | Q34107541 |
| | Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol | Q34307224 |
| | Short QT syndrome: pharmacological treatment | Q34314532 |
| | Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG | Q34661923 |
| | Right ventricular cardiomyopathy and sudden death in young people | Q34687427 |
| | The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5) | Q35097764 |
| | Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy | Q35770817 |
| | Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to β-blocker therapy in type 1 long-QT syndrome | Q36949265 |
| | Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome | Q37038494 |
| | Risks and challenges of implantable cardioverter-defibrillators in young adults | Q37332306 |
| | Prevalence of the congenital long-QT syndrome. | Q37442080 |
| | Prevalence of early-onset atrial fibrillation in congenital long QT syndrome | Q37613105 |
| | Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia. | Q37687517 |
| | Novel insight into the natural history of short QT syndrome. | Q37706496 |
| | Genetics of arrhythmogenic right ventricular cardiomyopathy: a practical guide for physicians | Q38090311 |
| | Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate | Q38106029 |
| | Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes | Q45027885 |
| | Pulmonary vein isolation in patients with Brugada syndrome and atrial fibrillation: a 2-year follow-up | Q45223897 |
| | Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia. | Q51094959 |
| | Short QT syndrome: successful prevention of sudden cardiac death in an adolescent by implantable cardioverter-defibrillator treatment for primary prophylaxis. | Q51491946 |
| | Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. | Q55638651 |
| | ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiolog | Q58973358 |
| | Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia | Q68182850 |
| | Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984 | Q69695239 |
| | Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities | Q77766277 |
| | Long QT Syndrome | Q82207682 |
| | Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up | Q82783650 |
| | Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium | Q83609756 |
| | The ICD for primary prevention in patients with inherited cardiac diseases: indications, use, and outcome: a comparison with secondary prevention | Q85812766 |
| | Quinidine, a life-saving medication for Brugada syndrome, is inaccessible in many countries | Q86589059 |
| | Arrhythmogenic right ventricular cardiomyopathy | Q87396206 |
| P433 | issue | 2 | |
| P407 | language of work or name | German | Q188 |
| P921 | main subject | congenital disorder | Q727096 |
| P304 | page(s) | 82-93 | |
| P577 | publication date | 2015-05-22 | |
| P1433 | published in | Herzschrittmachertherapie & Elektrophysiologie | Q27720965 |
| P1476 | title | Primary and secondary prophylactic ICD therapy in congenital electrical and structural cardiomyopathies | |
| P478 | volume | 26 | |